Skip to main content
Erschienen in: Pituitary 2/2018

03.01.2018

Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)

verfasst von: Nèle Lenders, Ann McCormack

Erschienen in: Pituitary | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, “silent” tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.
Literatur
1.
Zurück zum Zitat Lloyd RV, Osamura R, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, vol 10, 4 edn. IARC, Lyon Lloyd RV, Osamura R, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, vol 10, 4 edn. IARC, Lyon
3.
Zurück zum Zitat Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804–812PubMedCrossRef Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804–812PubMedCrossRef
5.
Zurück zum Zitat Doniach I (1992) Pituitary carcinoma. Clin Endocrinol 37(2):194–195CrossRef Doniach I (1992) Pituitary carcinoma. Clin Endocrinol 37(2):194–195CrossRef
9.
Zurück zum Zitat Negishi K, Suzuki T, Masuda Y, Masugi Y, Teramoto A, Ohama E (1988) Two autopsy cases of primary pituitary carcinoma. No To Shinkei 40(5):491–496PubMed Negishi K, Suzuki T, Masuda Y, Masugi Y, Teramoto A, Ohama E (1988) Two autopsy cases of primary pituitary carcinoma. No To Shinkei 40(5):491–496PubMed
10.
Zurück zum Zitat Mountcastle RB, Roof BS, Mayfield RK, Mordes DB, Sagel J, Biggs PJ, Rawe SE (1989) Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci 298(2):109–118PubMedCrossRef Mountcastle RB, Roof BS, Mayfield RK, Mordes DB, Sagel J, Biggs PJ, Rawe SE (1989) Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci 298(2):109–118PubMedCrossRef
13.
Zurück zum Zitat Molitch ME, Russell EJ (1990) The pituitary “incidentaloma”. Ann Intern Med 112(12):925–931PubMedCrossRef Molitch ME, Russell EJ (1990) The pituitary “incidentaloma”. Ann Intern Med 112(12):925–931PubMedCrossRef
14.
18.
Zurück zum Zitat Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2(2):117–122PubMedCrossRef Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2(2):117–122PubMedCrossRef
19.
Zurück zum Zitat Raverot G, Burman P, McCormack AI, Heaney AP, Petersenn S, Popovic V, Trouillas J, Dekkers O (2017) European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. https://doi.org/10.1530/EJE-17-0796 Raverot G, Burman P, McCormack AI, Heaney AP, Petersenn S, Popovic V, Trouillas J, Dekkers O (2017) European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. https://​doi.​org/​10.​1530/​EJE-17-0796
20.
Zurück zum Zitat McCormack AI, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P (2017) Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: results from a European Society of Endocrinology (ESE) survey. Endocr Abstracts. https://doi.org/10.1530/endoabs.49.OC12.2 McCormack AI, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P (2017) Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: results from a European Society of Endocrinology (ESE) survey. Endocr Abstracts. https://​doi.​org/​10.​1530/​endoabs.​49.​OC12.​2
21.
Zurück zum Zitat Lee JC, Pekmezci M, Lavezo JL, Vogel H, Katznelson L, Fraenkel M, Harsh G, Dulai M, Perry A, Tihan T (2017) Utility of Pit-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. Endocr Pathol. https://doi.org/10.1007/s12022-017-9503-6 Lee JC, Pekmezci M, Lavezo JL, Vogel H, Katznelson L, Fraenkel M, Harsh G, Dulai M, Perry A, Tihan T (2017) Utility of Pit-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. Endocr Pathol. https://​doi.​org/​10.​1007/​s12022-017-9503-6
29.
Zurück zum Zitat Roncaroli F, Scheithauer BW, Young WF, Horvath E, Kovacs K, Kros JM, Al-Sarraj S, Lloyd RV, Faustini-Fustini M (2003) Silent corticotroph carcinoma of the adenohypophysis: a report of five cases. Am J Surg Pathol 27(4):477–486PubMedCrossRef Roncaroli F, Scheithauer BW, Young WF, Horvath E, Kovacs K, Kros JM, Al-Sarraj S, Lloyd RV, Faustini-Fustini M (2003) Silent corticotroph carcinoma of the adenohypophysis: a report of five cases. Am J Surg Pathol 27(4):477–486PubMedCrossRef
30.
Zurück zum Zitat Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS (2015) SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer 22(1):111–119. https://doi.org/10.1530/ERC-14-0472 PubMedCrossRef Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS (2015) SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer 22(1):111–119. https://​doi.​org/​10.​1530/​ERC-14-0472 PubMedCrossRef
34.
Zurück zum Zitat Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150. https://doi.org/10.1159/000375448 PubMedCrossRef Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150. https://​doi.​org/​10.​1159/​000375448 PubMedCrossRef
35.
Zurück zum Zitat De Caro DB, Solari M, Pagliuca D, Villa F, Guadagno A, Cavallo E, Colao LM, Pettinato A, Cappabianca G (2017) P.: Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation: a series of 50 patients. Neurosurg Rev 40(1):105–114. https://doi.org/10.1007/s10143-016-0740-9 CrossRef De Caro DB, Solari M, Pagliuca D, Villa F, Guadagno A, Cavallo E, Colao LM, Pettinato A, Cappabianca G (2017) P.: Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation: a series of 50 patients. Neurosurg Rev 40(1):105–114. https://​doi.​org/​10.​1007/​s10143-016-0740-9 CrossRef
36.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon
37.
Zurück zum Zitat Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–106 (discussion 106–107)PubMedCrossRef Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–106 (discussion 106–107)PubMedCrossRef
40.
Zurück zum Zitat Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, members of HYPOPRONOS, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. https://doi.org/10.1007/s00401-013-1084-y PubMedCrossRef Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, members of HYPOPRONOS, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. https://​doi.​org/​10.​1007/​s00401-013-1084-y PubMedCrossRef
42.
Zurück zum Zitat Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4), 765–770 (discussion 770–761)PubMedCrossRef Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4), 765–770 (discussion 770–761)PubMedCrossRef
44.
Zurück zum Zitat Nudleman KL, Choi B, Kusske JA (1985) Primary pituitary carcinoma: a clinical pathological study. Neurosurgery 16(1):90–95PubMed Nudleman KL, Choi B, Kusske JA (1985) Primary pituitary carcinoma: a clinical pathological study. Neurosurgery 16(1):90–95PubMed
45.
Zurück zum Zitat Sakamoto T, Itoh Y, Fushimi S, Kowada M, Saito M (1990) Primary pituitary carcinoma with spinal cord metastasis–case report. Neurol Med Chir 30(10):763–767CrossRef Sakamoto T, Itoh Y, Fushimi S, Kowada M, Saito M (1990) Primary pituitary carcinoma with spinal cord metastasis–case report. Neurol Med Chir 30(10):763–767CrossRef
46.
Zurück zum Zitat Marques P, Mafra M, Calado C, Martins A, Monteiro J, Leite V (2014) Aggressive pituitary lesion with a remarkably high Ki-67. Arq Bras Endocrinol Metabol 58(6):656–660PubMedCrossRef Marques P, Mafra M, Calado C, Martins A, Monteiro J, Leite V (2014) Aggressive pituitary lesion with a remarkably high Ki-67. Arq Bras Endocrinol Metabol 58(6):656–660PubMedCrossRef
48.
Zurück zum Zitat Luzi P, Miracco C, Lio R, Malandrini A, Piovani S, Venezia SG, Tosi P (1987) Endocrine inactive pituitary carcinoma metastasizing to cervical lymph nodes: a case report. Hum Pathol 18(1):90–92PubMedCrossRef Luzi P, Miracco C, Lio R, Malandrini A, Piovani S, Venezia SG, Tosi P (1987) Endocrine inactive pituitary carcinoma metastasizing to cervical lymph nodes: a case report. Hum Pathol 18(1):90–92PubMedCrossRef
49.
Zurück zum Zitat Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12(3):329–341PubMedCrossRef Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12(3):329–341PubMedCrossRef
51.
Zurück zum Zitat Karavitaki N, Ansorge O, Wass JA (2007) Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51(8):1314–1318PubMedCrossRef Karavitaki N, Ansorge O, Wass JA (2007) Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51(8):1314–1318PubMedCrossRef
53.
Zurück zum Zitat Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M (2012) Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 15(3):276–287. https://doi.org/10.1007/s11102-011-0363-7 PubMedCrossRef Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M (2012) Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 15(3):276–287. https://​doi.​org/​10.​1007/​s11102-011-0363-7 PubMedCrossRef
57.
Zurück zum Zitat Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7PubMedCrossRef Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7PubMedCrossRef
59.
Zurück zum Zitat McCutcheon IE, Pieper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF (2000) Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery 46(5):1233–1239 (discussion 1239–1240)PubMedCrossRef McCutcheon IE, Pieper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF (2000) Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery 46(5):1233–1239 (discussion 1239–1240)PubMedCrossRef
60.
Zurück zum Zitat Koyama J, Ikeda K, Shose Y, Kimura M, Obora Y, Kohmura E (2007) Long-term survival with non-functioning pituitary carcinoma: case report. Neurol Med Chir 47(10):475–478CrossRef Koyama J, Ikeda K, Shose Y, Kimura M, Obora Y, Kohmura E (2007) Long-term survival with non-functioning pituitary carcinoma: case report. Neurol Med Chir 47(10):475–478CrossRef
67.
Zurück zum Zitat Alexandraki KI, Munayem Khan M, Chahal HS, Dalantaeva NS, Trivellin G, Berney DM, Caron P, Popovic V, Pfeifer M, Jordan S, Korbonits M, Grossman AB (2012) Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones 11(3):297–307PubMedCrossRef Alexandraki KI, Munayem Khan M, Chahal HS, Dalantaeva NS, Trivellin G, Berney DM, Caron P, Popovic V, Pfeifer M, Jordan S, Korbonits M, Grossman AB (2012) Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones 11(3):297–307PubMedCrossRef
68.
Zurück zum Zitat Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol 102(2):117–120PubMed Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol 102(2):117–120PubMed
73.
Zurück zum Zitat Jia W, Zhu J, Martin TA, Sanders AJ, Yang X, Cheng S, Yu H, Jia G, Liu X, Lu R, Jiang WG (2015) Expression of metastasis-associated gene-1 is associated with bone invasion and tumor stage in human pituitary adenomas. Cancer Genom Proteom 12(3):113–118 Jia W, Zhu J, Martin TA, Sanders AJ, Yang X, Cheng S, Yu H, Jia G, Liu X, Lu R, Jiang WG (2015) Expression of metastasis-associated gene-1 is associated with bone invasion and tumor stage in human pituitary adenomas. Cancer Genom Proteom 12(3):113–118
74.
Zurück zum Zitat Oystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J (2017) Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: sstr and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 102(9):3581–3590. https://doi.org/10.1210/jc.2017-00792 PubMedCrossRef Oystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J (2017) Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: sstr and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 102(9):3581–3590. https://​doi.​org/​10.​1210/​jc.​2017-00792 PubMedCrossRef
76.
Zurück zum Zitat Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO (1995) ACTH-producing pituitary carcinoma presenting as the cauda equina syndrome. Arch Pathol Lab Med 119(1):93–96PubMed Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO (1995) ACTH-producing pituitary carcinoma presenting as the cauda equina syndrome. Arch Pathol Lab Med 119(1):93–96PubMed
78.
Zurück zum Zitat Scheithauer BW, Randall RV, Laws ER Jr, Kovacs KT, Horvath E, Whitaker MD (1985) Prolactin cell carcinoma of the pituitary: clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer 55(3):598–604PubMedCrossRef Scheithauer BW, Randall RV, Laws ER Jr, Kovacs KT, Horvath E, Whitaker MD (1985) Prolactin cell carcinoma of the pituitary: clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer 55(3):598–604PubMedCrossRef
81.
Zurück zum Zitat Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40(2):225–236 (discussion 236–227)PubMedCrossRef Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40(2):225–236 (discussion 236–227)PubMedCrossRef
85.
Zurück zum Zitat Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assie G, Raverot G (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176(6):769–777. https://doi.org/10.1530/EJE-16-0979 PubMedCrossRef Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assie G, Raverot G (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176(6):769–777. https://​doi.​org/​10.​1530/​EJE-16-0979 PubMedCrossRef
86.
Zurück zum Zitat Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698. https://doi.org/10.1210/jc.2014-4350 PubMedCrossRef Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698. https://​doi.​org/​10.​1210/​jc.​2014-4350 PubMedCrossRef
87.
Zurück zum Zitat Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74(4):E447–E455. https://doi.org/10.1227/NEU.0000000000000251 (discussion E455)PubMedCrossRef Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74(4):E447–E455. https://​doi.​org/​10.​1227/​NEU.​0000000000000251​ (discussion E455)PubMedCrossRef
89.
Zurück zum Zitat Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592–4599. https://doi.org/10.1210/jc.2010-0644 PubMedCrossRef Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592–4599. https://​doi.​org/​10.​1210/​jc.​2010-0644 PubMedCrossRef
91.
Zurück zum Zitat Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761–E1767. https://doi.org/10.1227/NEU.0b013e318217161a (discussion E1767)PubMedCrossRef Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761–E1767. https://​doi.​org/​10.​1227/​NEU.​0b013e318217161a​ (discussion E1767)PubMedCrossRef
92.
Zurück zum Zitat Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130–1136. https://doi.org/10.1210/jc.2012-2924 PubMedCrossRef Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130–1136. https://​doi.​org/​10.​1210/​jc.​2012-2924 PubMedCrossRef
95.
Zurück zum Zitat Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16(3):1017–1027. https://doi.org/10.1677/ERC-08-0269 PubMedCrossRef Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16(3):1017–1027. https://​doi.​org/​10.​1677/​ERC-08-0269 PubMedCrossRef
101.
Zurück zum Zitat Richardson TE, Shen ZJ, Kanchwala M, Xing C, Filatenkov A, Shang P, Barnett S, Abedin Z, Malter JS, Raisanen JM, Burns DK, White CL, Hatanpaa KJ (2017) Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis. J Neuropathol Exp Neurol 76(10):874–882. https://doi.org/10.1093/jnen/nlx072 PubMedCrossRef Richardson TE, Shen ZJ, Kanchwala M, Xing C, Filatenkov A, Shang P, Barnett S, Abedin Z, Malter JS, Raisanen JM, Burns DK, White CL, Hatanpaa KJ (2017) Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis. J Neuropathol Exp Neurol 76(10):874–882. https://​doi.​org/​10.​1093/​jnen/​nlx072 PubMedCrossRef
103.
Zurück zum Zitat Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F, Cannavo S (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(Suppl 1):S57–S60. https://doi.org/10.1007/s11102-011-0373-5 PubMedCrossRef Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F, Cannavo S (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(Suppl 1):S57–S60. https://​doi.​org/​10.​1007/​s11102-011-0373-5 PubMedCrossRef
107.
108.
Zurück zum Zitat Waligorska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczynska M, Baszko-Blaszyk D, Blanco-Gangoo AR, Ruchala M (2016) Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report. J Neurosurg 125(2):346–349. https://doi.org/10.3171/2015.6.JNS15363 PubMedCrossRef Waligorska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczynska M, Baszko-Blaszyk D, Blanco-Gangoo AR, Ruchala M (2016) Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report. J Neurosurg 125(2):346–349. https://​doi.​org/​10.​3171/​2015.​6.​JNS15363 PubMedCrossRef
109.
Zurück zum Zitat Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37(4):810–815 (discussion 815–816)PubMedCrossRef Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37(4):810–815 (discussion 815–816)PubMedCrossRef
110.
Zurück zum Zitat Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290. https://doi.org/10.1210/jc.2010-0441 PubMedPubMedCentralCrossRef Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290. https://​doi.​org/​10.​1210/​jc.​2010-0441 PubMedPubMedCentralCrossRef
111.
Zurück zum Zitat Cartwright DM, Miller TR, Nasr AJ (1994) Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 11(1):68–73PubMedCrossRef Cartwright DM, Miller TR, Nasr AJ (1994) Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 11(1):68–73PubMedCrossRef
113.
Zurück zum Zitat He L, Forbes JA, Carr K, Nickols NH, Utz A, Moots P, Weaver K (2016) Response of silent corticotroph pituitary carcinoma to chemotherapy: case report. J Neurosurg Sci 60(2):272–280PubMed He L, Forbes JA, Carr K, Nickols NH, Utz A, Moots P, Weaver K (2016) Response of silent corticotroph pituitary carcinoma to chemotherapy: case report. J Neurosurg Sci 60(2):272–280PubMed
115.
Zurück zum Zitat Kumar K, Macaulay RJ, Kelly M, Pirlot T (2001) Absent p53 immunohistochemical staining in a pituitary carcinoma. Can J Neurol Sci 28(2):174–178PubMedCrossRef Kumar K, Macaulay RJ, Kelly M, Pirlot T (2001) Absent p53 immunohistochemical staining in a pituitary carcinoma. Can J Neurol Sci 28(2):174–178PubMedCrossRef
117.
Zurück zum Zitat Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones 10(2):162–167PubMedCrossRef Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones 10(2):162–167PubMedCrossRef
Metadaten
Titel
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)
verfasst von
Nèle Lenders
Ann McCormack
Publikationsdatum
03.01.2018
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 2/2018
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0857-z

Weitere Artikel der Ausgabe 2/2018

Pituitary 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.